Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754270 | 1.00 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL9344087 | 1.00 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL14747277 | 1.00 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL14747292 | 1.00 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL15721047 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL4619157 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL4619145 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL4621789 | 0.97 | CA1 (0.35) | CA1CA2CA9CA7TSHR | |
| SCHEMBL6102167 | 0.87 | TBXAS1 (0.44) | CA1CA2MMP2MMP3 | |
| SCHEMBL15892827 | 0.87 | CA1 (0.42) | CA1CA2CA9CA7TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244184-A1 | GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244184-A1 | GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME | ENGASE, GBA3, STS | CA1 244/4885CA2 187/4885CA9 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.